Researchers analyzed Medicare Part D prescription drug claims from 2017, drawing on a random sample representing 20 percent of Medicare beneficiaries and 224 drugs that had a generic substitute and at least 1,000 claims.
Their analysis found that the Medicare Part D program would have saved $977 million in 2017 if all branded prescription drugs requested by clinicians had been swapped with its generic substitute, and it would have saved an additional $673 million if all branded drugs requested by Medicare patients were swapped with a generic option, making for a total savings of $1.7 billion.
Of the 169 million filled prescriptions the research team analyzed, 8.5 million involved dispensing a brand name drug when a generic was available. Seventeen percent of those claims involved the clinician requesting a brand name drug over a generic, and 13.5 percent involved patients’ requests.
The study also found Medicare patients would have saved $270 million in 2017 if the dispensed brand name drugs with available generics were replaced with their generic option.
More articles on healthcare finance:
379 rare diseases cost healthcare $966B per year: study
Chicago safety net hospitals could lose $1.8B by 2024, study says
CMS to review geographic direct contracting payment model
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
